Astellas Pharma Inc. and Iveric bio, Inc. announced that on April 29, 2023 (Japan time), the companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$ 40.00 per share in cash for a total equity value of approximately US$ 5.9 billion (the
